Programmed cell death-ligand 2: new insights in cancer
Immunotherapy has revolutionized cancer treatment, with the anti-PD-1/PD-L1 axis therapy demonstrating significant clinical efficacy across various tumor types. However, it should be noted that this therapy is not universally effective for all PD-L1-positive patients, highlighting the need to expedi...
Main Authors: | Yukang Yang, Xia Yan, Xueqi Bai, Jiayang Yang, Jianbo Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359532/full |
Similar Items
-
Expression of Programmed Death Ligand-1 and Correlation with Clinicopathological Features and CD8 Infiltration in Breast Cancer
by: Shahenaz S Salih, et al.
Published: (2023-06-01) -
Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients
by: Karczmarczyk A, et al.
Published: (2022-03-01) -
Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
by: Feng Li, et al.
Published: (2022-06-01) -
Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders
by: Shangfeng eZhao, et al.
Published: (2014-09-01) -
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)